A new Northwestern Medicine study has identified the molecular mechanisms that cause a commonly prescribed antipsychotic drug ... works by blocking dopamine D2 receptors, which are highly ...

The Phase 3 test evaluated the drug, Cobenfy, as an adjunct to atypical antipsychotics in adults ... BMS said Cobenfy’s safety profile was consistent with prior tests of the drug.

New York, USA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- CAPLYTA’s Strong Market Adoption Propels Its Rise as a Leading Antipsychotic ... its differentiated safety profile and broad efficacy, it ...

Researchers from Regeneron Pharmaceuticals Inc. have described REGN-10597 (PD1-IL2Ra-IL2), a programmed cell death protein 1 (PD-1)-targeted, receptor-masked IL-2 immunocytokine.

Analysts at investment bank EF Hutton says, “This bodes well for Reviva’s Brilaroxazine, a multi-receptor ... presents a more typical profile for second-generation antipsychotics, including ...

First-generation antipsychotics, dating back to the 1950s, targeted the postsynaptic dopamine 2 (D2) receptor ... have a clinical efficacy and safety profile to help improve patient outcomes ...

The study, including experiments in mice, offers early evidence in support of co-administering antipsychotic medications that block dopamine (DA) D 2-like receptors in the brain alongside drugs ...

Most prescription antipsychotic medications work by blocking the class of brain receptors that respond ... bromocriptine that improves the glucose profile of insulin-resistant mice, peripherally ...

Trace amine-associated receptor 1 (TAAR1) is a member of the G protein-coupled ... Shandong University investigators have recently reported the discovery of a novel TAAR1 agonist as an antipsychotic ...

Both first- and second-generation antipsychotics affect the risk for TD development because of the way they work on the brain, which involves blocking dopamine receptors (D2 receptors) in the ...